HPB Virtual Tumor Board, Monday, July 27

• multimodality treatment options regarding surgical decision making in both resectable and borderline resectable disease
• current data from major clinical trials involving multimodality neoadjuvant and adjuvant therapy for resectable and borderline resectable disease
• current definitions of resectable and borderline resectable pancreas cancer including technical, vascular and medical resectability

The case scenarios to be discussed will include:

• The role of medical co-morbidities in defining resectable disease and prehabilitation strategies
• The approach to resectable disease (upfront surgery vs neoadjuvant, chemotherapy/radiation, and how long)
• The approach to borderline resectable disease (neoadjuvant strategies, chemotherapy/radiation, what agents/types, length)

Moderators, Presenters and Discussants on this panel include: Melissa Hogg, MD from Northshore University Health System; Alexander Parikh, MD from East Carolina University Brody School of Medicine; George Poultsides, MD from Stanford University; Jashodeep Datta, MD from the University of Miami Health System; Carrie Luu, MD from Saint Louis University Hospital; Ugwuji Maduekwe, MD from University of North Carolina Chapel Hill.